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Abstract
Signal transducer and activator of transcription (STAT)-3 inhibitors play an important role in
regulating immune responses. Galiellalactone (GL) is a fungal secondary metabolite known to
interfere with the binding of phosphorylated signal transducer and activator of transcription
(pSTAT)-3 as well of pSTAT-6 dimers to their target DNA in vitro. Intra nasal delivery of 50 mg GL into
the lung of naive Balb/c mice induced FoxP3 expression locally and IL-10 production and IL-12p40 in
RNA expression in the airways in vivo. In a murine model of allergic asthma, GL significantly
suppressed the cardinal features of asthma, such as airway hyperresponsiveness, eosinophilia and
mucus production, after sensitization and subsequent challenge with ovalbumin (OVA). These
changes resulted in induction of IL-12p70 and IL-10 production by lung CD11c1 dendritic cells (DCs)
accompanied by an increase of IL-3 receptor a chain and indoleamine-2,3-dioxygenase expression in
these cells. Furthermore, GL inhibited IL-4 production in T-bet-deficient CD41 T cells and down-
regulated the suppressor of cytokine signaling-3 (SOCS-3), also in the absence of STAT-3 in T cells, in
the lung in a murine model of asthma. In addition, we found reduced amounts of pSTAT-5 in the lung
of GL-treated mice that correlated with decreased release of IL-2 by lung OVA-specific CD41 T cells
after treatment with GL in vitro also in the absence of T-bet. Thus, GL treatment in vivo and in vitro
emerges as a novel therapeutic approach for allergic asthma by modulating lung DC phenotype and
function resulting in a protective response via CD41FoxP31 regulatory T cells locally.
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Introduction
Dendritic cells (DCs) control the activation and maturation of
CD4+ T helper (Th cells) and determine key steps in innate
and adaptive immunity (1, 2). Current therapies for allergic
asthma enclose glucocorticoids that suppress inflammatory
cytokines, (3) such as IL-6 and IL-4, released by antigen-
presenting cells and NK cell subsets (4–8). Steroid-induced
immune tolerance has beneficial effects on allergic asthma
via Toll-like-receptor-mediated reduced DC maturation (9).
Whether DCs are immunostimulatory, anergic or tolerogenic
depends on their expression of regulatory surface molecules
and intracellular transcription factors defining their immunopa-
thogenic character mediated by the cytokines they release.
The transcription factor signal transducer and activator of
transcription (STAT-3), a protein induced and phosphorylated
via IL-6 or IL-10 (10) cytokine signaling, controls activation and
function of CD4+ T cells by tolerogenic DCs (11) induction and
is critical for the development of regulatory T (T reg) cell popu-
lations (12). It has been previously demonstrated that galiella-
lactone (GL), a fungal secondary metabolite isolated from the
ascomycete Galiella rufa (13), inhibited STAT-3-dependent
(IL-6) and STAT-6-dependent (IL-4) reporter gene expression
with high selectivity resulting in decreased activated STAT-3
dimer binding to the target promoter (14). Since suppressor of
cytokine signaling-3 (SOCS-3) proteins (15) are known to be in-
hibitory to IL-6/STAT-3 signaling and to regulate onset and
maintenance of Th2-mediated allergic responses, we reasoned
that the decrease of activated lung STAT-3 binding on its target
DNA (16) would interfere with SOCS-3 expression.
Consistently, intra-nasal application of GL decreased lung
Th2 cells, lung IL-17A-producing cells, while it induced Th1
cells, the expression of indoleamine-2,3-dioxygenase (IDO)
and regulatory CD4+ T cells in the lung. GL-mediated T-cell
responses were accompanied by inhibition of STAT-3–STAT-5
DNA binding/activation resulting in increased anti-
inflammatory cell subsets expansion.
In conclusion, GL treatment ameliorated experimental
asthma by inducing a tolerogenic milieu by changing the
DC subsets (17) by STAT-3 inhibition, thus providing a new
possible therapeutic approach for this disease.
Methods
Mice
Balb/cJ mice were purchased from the animal facility of the
Universita¨tsmedizin Mainz. T-bet-deficient mice were kindly
provided to us by Prof. Laurie Glimcher, Harvard Medical
School, Boston, MA. T-cell-specific STAT-3-deficient mice
were generated by Prof. K. Takeda in the laboratory of Prof.
S. Akira who kindly provided them to us. These mice were
previously described (18).
Producing organism, fermentation and isolation of GL
GL was purified from the ascomycete IBWFA111-95 iso-
lated from wood (13). The strain was kindly provided by
Prof. H. Anke and is deposited in the culture collection of
the Institute for Biotechnology and Drug Research (IBWF
e.V., Kaiserslautern, Germany). For maintenance on agar
slants, the strain was kept on YMG medium composed of
yeast extract 0.4%, malt extract 1%, glucose 1%, pH 5.5,
and agar 1.5% for solid media. Fermentations were carried
out in a Braun Biostat A-20 fermenter containing 20 l of
YMG medium with aeration (3 l air min1) and agitation
(120 r.p.m.) at 22C. The production of GL was followed by
analyzing mass and ultraviolet (UV) spectra of daily culture
fluid samples (50 ml) extracted with an equal volume of
ethyl acetate (EtOAc), evaporated to dryness and resolved
in methanol at a concentration of 5 mg ml1. The mass
and UV spectra were analyzed with a Hewlett–Packard Se-
ries 1100LC-MSD instrument fitted with a LiChroCART
Superspher 100 RP-18 column (125 3 2 mm, 4-mm particle
size; Merck, Darmstadt, Germany). The chromatographic
conditions consisted of a gradient from 1 to 100% acetoni-
trile in 20 min and an isocratic step at 100% acetonitrile for
1 min at 40C and 10 ll injection volume was used. The
flow rate was 0.45 ml min1. The fragmentor voltage was
set to 140 V in the positive and negative atmospheric pres-
sure chemical ionisation (APCI) modes. The spectra
obtained were compared with the reference library of the
IBWF e. V.. After 700 h of fermentation, the culture fluid
was separated from the mycelium by filtration and
extracted with EtOAc. The solvent was evaporated and the
crude product (2.3 g) was separated by chromatography
on silica gel (Merck 60) with cyclohexane:EtOAc (70:30) as
eluant resulting in 1.2 g of an enriched product. Preparative
HPLC (Macherey–Nagel Nucleosil 100-7 C-18, column 40 3
250 mm) with water:MeOH (46:54) as eluant yielded 635 mg
of GL. The purity of the isolated GL was analyzed by HPLC-
DAD/MS using the conditions described above. GL showed
the highly characteristic fragmentation pattern in the APCI-
positive mass spectrum revealing the molecular ion (Fig. 1A).
The purity of GL as estimated by HPLC-DAD/MS analysis
was >97.5% (Fig. 1A).
The naive compound is resistant to heat or other inactiva-
tion methods in comparison with proteins and it has passive
diffusion properties in target cells. GL in naive form was then
dissolved in ethanol in our laboratories to 10 mg ml1 as
stock solution and diluted with nine parts of PBS. For intra-
nasal therapy, 50 lg or accordingly 100 lg (in 50 ll) per in
vivo treatment was used. In vitro studies were performed
with primary lung CD4+ T cells treated with GL used at
equivalent concentrations (125 ng GL per 106 cells ml1 in
vitro equivalent to 25 lg in vivo up to 500 ng ml1 equivalent
to 100 lg GL in vivo taking into account the average number
of total lung cell isolated per lung) dissolved in RPMI
enriched by 5% fetal calf serum.
Allergen sensitization, intra-nasal GL treatment and
ovalbumin challenge in mice
Six- to eight-week-old female naive Balb/cJ mice were
anesthetized with Avertine solution and subsequently trea-
ted with PBS-diluted GL in concentrations of 50 lg up to
100 lg GL per intranasal treatment for three consecutive
days. Control mice received 10% ethanol (1:10 in PBS) in-
tranasally instead. In the acute experimental asthma proto-
col, mice were sensitized with ovalbumin (OVA) intra-
peritoneally at day 0 and 14 and challenged with OVA in
PBS per aerosol (10 mg OVA/ml PBS) (OVA/OVA) at days
25, 26 and 27. Two hours before each allergen challenge,
mice were treated intra-nasally with GL as described
above. Intranasal applications were performed as previ-
ously described (12).
At day 28, airway hyperresponsiveness (AHR) was mea-
sured by invasive plethysmography, bronchoalveolar lavage
fluid (BALF) was collected and all mice were sacrificed for lung
molecular analyses as previously described (19, 20). AHR data
are reported as airway resistance (RL) above the baseline
value. Data are expressed as mean values of RL 6 SEM. His-
tological sections were performed from formalin-stored lungs
as previously described (20, 21). T-bet-deficient mice have
been previously described in a setting of experimental asthma
(22). All animal experiments have been approved by the
ethical committee of Rheinland Pfalz, Germany.
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CD11+ cells, CD4+ T cells and CD4 cells isolation and
culture
Murine CD11c+ cells were isolated from the lung as previ-
ously described (23). Purified CD11c+ cells were cultured
overnight in 500 lg ml1 OVA and 5% fetal calf serum in
RPMI medium (2.5 3 105cells per well). Lung CD4+ T cells
were purified as well by using immunomagnetic separation
as previously described (24). Lung CD4+ T cells were
Fig. 1. GL treatment reduced pSTAT-3 in naive splenic CD4+ T cells and induced lung FoxP3, IL-12p40 and IL-10 expression. (A) Upper panels:
structure and mass spectrum of GL; lower panels: analysis of purified GL by UV signals at 210 nm (left-hand side panel) and detection of APCI-
positive signal fragments (right-hand side panel). (B) Induction of lung FoxP3 protein expression (P = 0.023; n = 3); IL-10 release in the airways
(C; P = 0.046; n = 3) and IL-12p40 mRNA expression (D; P = 0.0023; n = 3) in the lung after GL (50 lg per intra-nasal treatment) in naive mice.
(E) PSTAT-3 staining of splenic CD4+ T cells pre-treated with IL-6. GL treatment reduced, in a dose-dependent manner, the number of pSTAT-
3+CD4+ T cells that were pre-activated with IL-6 (20 ng ml1) (P = 0.032; n = 3). Data are shown as mean values 6 SEM. *P < 0.05; **P < 0.01.
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cultured in the presence of anti-CD28 (2 lg ml1) overnight
after coating for 1 h at 37C with anti-CD3 antibodies
(2.5 lg ml1) and analyzed for cytokines in their superna-
tants as described previously (25). Lung CD4 T cells were
isolated by separating them from CD4+ T cells by magnetic
bead sorting. Cells were then cultured overnight in RPMI
medium supplemented with 500 lg ml1 OVA. Then, CD11c
and CD123 expression was measured in those cells by
FACS as described previously (26). Moreover, RNA was
extracted for detection of indoleamine-2,3-dioxygenase
(IDO) by quantitiative real-time PCR as described below.
Immunohistochemistry
Splenic CD4+ T cells were incubated for 30 min with recombi-
nant murine IL-6 (20 ng ml1) alone or with the indicated con-
centrations of GL in the presence of anti-CD3 (2.5 lg ml1)
and soluble anti-CD28 antibodies (2 lg ml1) in duplicated
wells. After that, cells were frozen for subsequent detection of
pSTAT-3 expression. For immunodetection of pSTAT-3, cells
were fixed in 2% paraformaldehyde in PBS for 10 min and
washed twice in PBS. Cells were then permeabilized for 4 min
in permeabilization buffer (0.2% Triton X-100 in PBS) and
washed twice in Tris-buffered saline (TBS) buffer (0.05 M Tris
hydrochloride). After 40 min of incubation in blocking buffer
(3% BSA and 0.05% Tween 20 in TBS), a rabbit polyclonal
anti-pSTAT-3 (Tyr705) antibody (Cell Signaling Technology,
Danvers, MA, USA) was applied (1:50) in blocking buffer and
incubated overnight at 4C. Detection of positive cells was per-
formed after cells in wells were incubated with a biotinylated
goat anti-rabbit antibody solution (Vector Laboratories Inc.;
1:200 in blocking buffer) for 30 min. Finally, the Cy2–streptavi-
dine solution (1:500 in PBS) was added, followed by incubation
for 60 min at room temperature. The cells in wells were finally
washed three times in PBS. Cells were then analyzed with an
inverted fluorescence microscope (Zeiss) at both 200- and
400-fold magnifications.
RNA isolation and real-time PCR
Total lung tissue and purified lung cells were homogenized
and RNA was then extracted by using PeQ-Gold for tissue
disruption (PeQLab, Erlangen, Germany) or RNA Micro Kit
(Qiagen, Hilden, Germany) for RNA preparation from iso-
lated cells. RNA (1 lg) was used for cDNA generation using
the first strand cDNA synthesis kit for reverse transcription–
PCR (MBI Fermentas, St Leon-Rot, Germany). The resulting
template cDNA was amplified by quantitative real-time PCR
by using specific primers (see below) in 20-ll reactions in
an iCycler (BioRad). For IDO and hypoxanthine phosphori-
bosyl transferase 1 (HPRT) quantitative PCR (5 min at 95C
and 40 cycles of 15 s at 94C, 60 s at 60C), an SYBR
greenTM (Thermo Fisher Scientific, Dreieich, Germany) tech-
nique for DNA labeling was used. For the housekeeping gene
HPRT(NM_013556), the following sequences of the primers
were used: 5#-GCCCCAAAATGGTTAAGGTT-3# as forward
primer and 5#-TTGCGCTCATCTTAGGCTTT-3# as reverse
primer. The primers used to detect IDO (NM-008324) had the
following sequence: forward primer, 5#-AAGGGCTTCTTC-
CTCGTCTC-3# and reverse primer, 5#-AAAAACGTGTCTGG-
GTCCAC-3#. FoxP3 (NM-054039) was detected with a forward
primer with the sequence 5#-AGAAGCTGGGAGCTATGCA-
GG-3# and a reverse primer with the sequence 5#-GGCTAC-
GATGCAGCAAGAGC-3#. For IL-12p40 (NM-008352) quanti-
tative TaqMan-PCR studies, the following primers were used:
5#-TACTCCGGACGGTTCACGTG-3# and 5#-GTCACTGCC-
CGAGAGTCAGG-3#. All primers were designed using the
primer3plus-software (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi) and the mRNA sequences
indicated.
Protein extraction and western blot analysis
Tissue proteins were extracted and protein concentration
was determined as described previously (19). Mouse mono-
clonal antibodies against FoxP3 were purchased from
e-bioscience (San Diego, CA, USA). Additional rabbit poly-
clonal antibodies against SOCS-3 (Upstate, Billerica, MA,
USA) and goat polyclonal antibodies against b-actin were
purchased from Santa Cruz Biotech (Heidelberg, Germany).
Polyclonal pSTAT-6, pSTAT-5 and STAT-5 antibodies from rab-
bit origin were purchased from Cell Signaling. Western blot
analysis was done as previously reported (21) and quanti-
fied by densitometrical analysis (BioAnalyzeTM; Biometra,
Go¨ttingen, Germany).
Enzyme-linked immunosorbent assay
Mouse IL-2, IL-4, IL-6, IFN-c, IL-10 and IL-12p70 were
detected using a specific sandwich ELISA (all purchased from
OptEIATM; BD Pharmingen, Heidelberg, Germany). IL-17A was
detected by using a DuoSet Kit (R&D Systems, Wiesbaden,
Germany). Transforming growth factor (TGF)-b1 monomers
were quantified from BALF as described previously (25).
FACS analysis
The primary cells isolated from lung or spleen were stained
with antibodies directed against immunosuppressive DC
markers like FITC-conjugated anti-CD11c (BD Pharmingen),
anti-CD123 (PE conjugated; e-Bioscience). CD4+ T cells
were analyzed with anti-CD4-APC (e-Bioscience), CD69-
FITC and CD44-Cy7 (BD Pharmingen). Intracellular staining
for FoxP3 (e-bioscience), a marker for Treg cells, was per-
formed as described previously (27). All antibodies were di-
luted from 60 up to 120 ng per 100 ll in PBS per 5 3 105
total lung cells for cellular surface staining as previously
standardized (26).
Statistical analysis
Values were evaluated for statistically significant differences
(P < 0.05) by the Student’s two-tailed t-test for independent
events (Excel, PC). Data are given as mean values 6 SEM.
A two-way analysis of variance (ANOVA) test was used to
determine the statistical significant differences of the AHR
measurements among the group of mice (28).
Results
GL induces FoxP3 and IL-10 in naive lungs in vivo
GL is a known inhibitor of STAT-3 that was isolated from the
ascomycete G. rufa after biofermentation by using chemical
purification steps and HPLC techniques. GL and its mass
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spectrum are shown in Fig. 1A (upper left and right panel,
respectively). Analysis of purified GL by UV signals at 210 nm
(Fig. 1A, lower left-hand side panel) and detection of APCI-
positive signal fragments (Fig. 1A, lower right-hand side
panel) are shown.
To test the effects of GL in naive lungs in vivo, we treated
in an initial series of studies naive Balb/c mice intra-nasally
with GL for three consecutive days at days 1, 2 and 3 with
50 lg in 50 ll. Twenty-four hours after the last intra-nasal
GL treatment, the airway hyperresponsiveness (AHR) was
Fig. 2. Protective effect after local GL treatment in experimental murine allergic asthma before and during allergen challenge. (A) AHR was inhibited
in mice treated with a moderate dose of 50 lg GL after OVA sensitization, before and during challenge compared with control mice [P = 0.038
(3 mg ml1), n = 10 and P = 0.024 (10 mg ml1), n = 10 in a student’s t-test]. A two-way ANOVA analysis of all values was also performed [P = 0.042
by comparing RL/baseline values (% of baseline) of OVA untreated with OVA +GL (50 lg) treated mice]. Higher doses of GL did not significantly
ameliorate lung function. (B) In at least three independent experiments of five mice per group H&E and PAS (mucus) staining were performed. In an
acute model of asthma, the effect on airway inflammation after GL at a dose of 50 lg per intra-nasal treatment was analyzed. As shown, OVA-induced
mucus hyper-production was significantly decreased by GL treatment (P = 0.041; n = 6) (lower panels). No significant effect was observed on the
peribronchial infiltration of inflammatory cells (upper and middle panels). (C) Total lung proteins were isolated and western blot analysis was
performed for pSTAT-3. The values were corrected for b-actin. No significant difference was observed between groups in pSTAT-3 expression after
OVA sensitization and challenge (P = 0.235; n = 3). (D) Eosinophils (P = 0.032; n = 5) as well as mononuclear cell number (P = 0.002; n = 5) were
decreased in the BALF after OVA and GL (50 lg) treatment as compared with untreated control mice. Absolute numbers (left panel) were obtained by
multiplication of the values in percentage (right panel) and the total cell numbers per ml of BALF obtained after counting with a cytometer. One
representative experiment out of three is shown. Data are shown as mean values 6 SEM. *P < 0.05; **P < 0.01.
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measured and bronchoalveolar lavage was performed.
Immediately after that, the mice were sacrificed and total
lung protein and mRNA were isolated and analyzed using
western blot and real-time PCR analysis, respectively. It
was found that such a local GL treatment induced FoxP3
protein levels in the lung as compared with control un-
treated mice (Fig. 1B). As shown in Fig. 1C, IL-10 protein
release in the bronchoalveolar lavage and IL-12p40 mRNA
(Fig. lD) in the lung were found to be increased in GL-
treated mice. GL intra-nasal administration without any
allergen sensitization and challenge did not influence spon-
taneous AHR or inflammation (data not shown), despite the
fact that it induced IFN-c release in the BALF and in the
lung CD4+ T-cell supernatants under co-stimulatory condi-
tions (Supplementary Figure SI is available at International
Immunology Online). Thus, local treatment with GL may be
used as a strategy to induce Th1 and immunosuppressive
responses before antigen exposure without modulating basal
levels of AHR and lung inflammation.
Since IL-6 signaling is important for Treg cells and Th17 de-
velopment, we then looked for specific IL-6 signaling. To this
aim, we analyzed pSTAT-3 expression after GL treatment
in vitro in isolated naive spleen CD4+ T cells. It is known that
STAT-3 binding to target promoter is inhibited by GL in
HepG2 hepatocytes (14) and Supplementary Figure SII (avail-
able at International Immunology Online). As shown in
Fig. 1E, GL inhibited the number of CD4+pSTAT-3+ T cells
after immunohistological staining of IL-6-treated spleen CD4+
T cells. Thus, GL selectively inhibits IL-6/STAT-3 signaling in
CD4+ T cells in a dose–response manner (Fig. 1E, lower
panels and as quantified in a graph on the right-hand side).
Protective effect of galiellalactone therapy on allergen-
induced AHR and pathology
In subsequent studies on the therapeutic use of GL in OVA-
sensitized mice, we found that mice treated with 50 lg but
not with 100 lg of GL for three consecutive days immedi-
ately before as well as during allergen challenge showed
significantly ameliorated methacholine-induced airway
hyperresponsiveness (AHR) compared with control mice
(Fig. 2A). Moreover, GL (50 lg) treatment led to a selective
decrease in airway mucus production without significantly
changing other classical airways inflammatory parameters
as compared with untreated control mice (Fig. 2B). Under
these experimental conditions, no significant change in to-
tal lung pSTAT-3 was observed (Fig. 2C). Moreover, the
number of infiltrating eosinophils was also found to be re-
duced in the BALF of GL-treated mice as compared with
that of untreated mice (Fig. 2D). Taken together, these data
demonstrated a marked therapeutic effect of GL at a dose
of 50 lg in a murine model of OVA-induced allergic
asthma.
GL intra-nasal treatment induced Th1 and TGF-b1 and
decreased IL-4 in the airways of antigen-sensitized and
challenged mice
GL is known to inhibit pSTAT-3 DNA binding (14) and STAT-3
phosphorylation in lung CD4+ T cells (Fig. 1E) and therefore
might target several cytokine and transcription factor pro-
moter activities and gene expression, e.g. IL-4, IL-6, IL-10
and accessory signaling molecules. For this reason, we
analyzed Th1-inducing cytokines upon GL treatment in ex-
perimental asthma. We observed that IL-12p40 mRNA was
up-regulated in the airways of GL-treated mice compared
with control, untreated naive mice (Fig. 1D). However,
IL-12p40 is a part of both IL-23 and IL-12p70. Since
Fig. 3. GL-treated mice have increased IL-12p70 and IFN-c and
decreased IL-4 levels in their airways in a murine model of asthma.
(A) IL-12p70 was found to be increased in the airways of GL (50 lg)-
treated mice (P = 0.048; n = 4) along with IFN-c, the signature Th1
cytokine (B) (P = 0.034; n = 5). (C) IL-4 was found to be decreased in
the airways of GL-treated mice as compared with untreated control
mice (P = 0.006; n = 6). (D) TGF-b1, a suppressor cytokine that
induces and is also produced by Treg cells, was increased by GL
treatment in a murine model of asthma (P = 0.049; n = 4). One
representative experiment out of two is shown. Data are represented as
mean values 6 SEM. *P < 0.05; **P < 0.01.
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IL-12p70 induces Th1, whereas IL-23 is known to support
the development of the pro-inflammatory Th17 cells, we
then looked at IL-12p70 protein production by ELISA in
a murine model of asthma after OVA sensitization and
challenge in untreated and GL-treated mice (Fig. 3A).
As shown, GL induced IL-12p70 (p35/p40 heterodimer)
Fig. 4. Lung and splenic CD123hi CD11c+ cells released more IL-10 and IL-12p70 in the airways after GL treatment in a murine model of allergic
asthma. (A) Increased number of lung CD11c+ cells express CD123 (IL-3 receptor a) on their surface if isolated from GL (50 lg)-treated mice
compared with those isolated from untreated control littermates after OVA sensitization and challenge (P = 0.004, n = 4). (B) CD4 splenocytes
were cultured in vitro without and with GL (250 ng ml1) (upper panels) and afterward co-cultured with GL-pre-treated splenic CD4+ Tcells (lower
panels). FACS analysis was performed after staining for CD11c and CD123. Splenic CD4 cells treated in vitro with GL expressed increased
number of CD11c+CD123+ as compared with untreated cells (upper panels). Additionally, GL-pre-treated splenic CD4+ Tcells further induced the
CD11c+CD123+ cell population in GL-treated splenic CD4 cells (P = 0.008; n = 5). (C and D) CD11c+ cells isolated from the lungs of GL
(50 lg)-treated mice released increased IL-10 (C) and IL-12p70 (D) compared with those isolated from untreated control mice (P < 0.001; n = 3
and P = 0.039; n = 4, respectively). (E) Lung CD11c+ cells express increased amounts of indoleamine-2,3-dioxygenase (IDO) mRNA after GL
(50 lg) treatment in vivo and after OVA recall (500 lg ml1) in vitro (P = 0.047; n = 3). One representative experiment out of two is shown. Data
are represented as mean values 6 SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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when applied intra-nasally before and during allergen
challenge as well as the mRNA expression of p40 in
naive mice (see Fig. 1D). Consistent with the increase of
IL-12p70 in the BALF, we found up-regulation of the
signature cytokine of Th1 cells, IFN-c (Fig. 3B), and a de-
crease of the Th2 cytokine IL-4 (Fig. 3C) in the airways of
OVA-sensitized and -challenged GL-treated mice com-
pared with the OVA/OVA untreated control mice. Therefore,
GL therapy might prevent AHR and airway eosinophilia by
inducing a Th1 phenotype as well as by inhibiting Th2 cells
locally. The pro-inflammatory effect of GL at higher doses
is at the moment not well understood but it could be that
high levels of IFN-c in the airways after application of
higher doses of GL might negatively influence inflammation
and other parameters in experimental asthma.
Furthermore, TGF-b1, a cytokine with the capacity to stim-
ulate the differentiation of Th17 as well as Treg cells, was
found to be increased in the airway of GL-treated mice com-
pared with the control untreated mice after allergen
challenge (Fig. 3D).
Increased IL-10 and IL-12p70 release by lung DC isolated
from GL-treated mice
We next asked whether the change in cytokine production
in the BALF would reflect changes in local lung DCs’ char-
acter. To this aim, we analyzed the number of cells co-
expressing CD11c and CD123 (IL-3-receptor-a), a marker
of immunosuppressive myeloid DCs. It was found that they
were increased after GL therapy (Fig. 4A). To demonstrate
a direct effect of GL on DCs, we isolated splenic CD4-
negative cells (CD4), treated them with GL (+GL; 250 ng
GL per ml RPMI, 5% FCS) or left them untreated (GL)
and 24 h later analyzed the expression of CD123 and
CD11c. As shown in Fig. 4A, GL induced the expression
the IL-3 receptor a chain (CD123) on those cells. Moreover,
when CD4 cells were incubated overnight with
250 ng ml1 GL (+GL) and then co-cultured again over-
night with an equal number of GL-treated (250 ng ml1)
CD4+ T cells (+GL), an induction of CD11c+CD123+ cells
mediated by the GL-primed CD4+ T cells was found (Fig. 4B,
lower panel). Therefore, we next focused on cytokine produc-
tion of isolated lung CD11c+ cells after GL treatment. In-
creased protein levels of IL-10 and IL-12p70 were measured
in the supernatants of lung CD11c+ cells isolated from GL-
treated mice compared with those isolated from untreated
control mice (Fig. 4C and D, respectively). These findings
indicate an expansion of the DC-1 population that released
enhanced levels of IL-10 and IL-12 in the lung after GL treat-
ment. Thus, GL treatment might prevent experimental
asthma because it affects CD11c+ cell cytokine production
(IL-10) (17) and induces their ability to prime CD4+ T cells
to develop into Treg cells. Additionally, we found increased
Fig. 5. GL inhibited IL-4 release by T-bet(/) lung CD4+ T cells
isolated from OVA-sensitized and -challenged mice. (A) Lung CD4+ T
cells isolated from the lungs of GL (50 lg)-treated mice contain
significantly lower number of CD44- and CD69-positive cells,
indicating decreased activation of lung CD4+ T effector cells
(P = 0.005; n = 4) upon GL treatment. (B–C) Under co-stimulatory
conditions, lung CD4+ T cells isolated from GL-treated mice released
increased amounts of IFN-c (B), whereas IL-4 (C) was down-regulated
in these cell supernatants as compared with those obtained from lung
CD4+ T cells isolated from untreated mice. Supernatants were
measured by ELISA after overnight culture (P = 0.03, n = 4 and
P = 0.025, n = 4, respectively). (D) In T-bet-deficient lung CD4+
T cells, IL-4 was suppressed in a dose-dependent manner by GL
in vitro [P = 0.021, n = 2 for GL (125 ng ml1); P = 0.006, n = 3 for
GL (250 ng ml1) and P < 0.001, n = 2 for GL (500 ng ml1)]. One
representative experiment out of three is shown. Data are represented
as mean values 6 SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 6. Down-regulation of Th17 cells in the lung of GL-treated mice compared with control untreated mice in a murine model of allergic asthma.
GL (50 lg)-treated mice released decreased levels of IL-6 (A) in the airways and in lung CD4+ T-cell supernatants (B) as compared with OVA-
sensitized and untreated control mice (P = 0.049; n = 3). (C) Lung CD4+ T cells from in vivo GL-treated mice released increased amounts of
TGF-b1 after OVA sensitization and challenge (P = 0.049; n = 3). (D) In addition, a decreased IL-17A level was found, probably as a result of GL-
dependent decrease of IL-6 release by CD4+ T cells was observed (P = 0.045; n = 3). One representative experiment out of two is shown. Data
are represented as mean values 6 SEM. *P < 0.05.
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mRNA expression of indoleamine-2,3-dioxygenase (IDO) in
lung CD11c+ cells treated with OVA and GL (Fig. 4E). Plas-
macytoid DCs expressing IDO are known to be potent
inducers of differentiation of Treg cells and therefore are
able to maintain an immunosuppressive tolerance in the
lung (29).
Fig. 7. GL-treated splenic CD4 cells enhanced FoxP3 and IL-10 expression in splenic untreated CD4+ T cells. Since TGF-b1 is known to induce
FoxP3, we then analyzed the expression of FoxP3 in lung CD4+ T cells in GL (50 lg)-treated and control mice in a murine model of allergic
asthma. (A) Consistent with the findings in naive mice, lung FoxP3 mRNA was increased in GL (50 lg)-treated mice compared with the control
littermates after OVA sensitization and OVA challenge (P = 0.0013; n = 6, respectively). (B) Lung CD4+ T cells also released increased amounts
of IL-10 indicating the presence of Treg cells after local GL treatment (P = 0.005; n = 3). (C) OVA-sensitized and -challenged mice treated intra-
nasally with 50 lg GL before and during allergen challenge showed increased numbers of lung CD4+ T cells expressing FoxP3 after FACS
intracellular analysis (P = 0.019; n = 4). (D) FoxP3 expression was induced in GL-treated splenic CD4+ T cells (P = 0.021; n = 4; left-hand side
lower panels). FoxP3 expression in untreated CD4+ T cells was also significantly increased after co-culture (1:1) with splenic CD4 cells pre-
incubated for 24 h with GL (250 ng ml1) compared with untreated splenic CD4 cell co-culture (P < 0.001, n = 4; -right-hand side panels). One
representative experiment out of three is shown. Data are represented as mean values 6 SEM. *P < 0.05; **P < 0.01.
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GL inhibited IL-4 release by lung CD4+ T cells isolated from
T-bet-deficient mice
We next isolated CD4+ T cells from the lung of GL-treated
and untreated mice after OVA sensitization and challenge
and measured their activation state (Fig. 5A). As shown, the
CD4+ T cells isolated from the lung of OVA-sensitized
and -challenged (OVA/OVA) and GL-treated mice have a less
activated phenotype compared with those isolated from un-
treated mice. Moreover, CD4+ T cells isolated from the lung
of GL-treated mice displayed a Th1-like phenotype rather
than a Th2-like phenotype as demonstrated by increased
IFN-c (Fig. 5B) and decreased IL-4 (Fig. 5C) levels in their
supernatants compared with lung CD4+ T cells isolated from
untreated and OVA-sensitized and -challenged and un-
treated mice. Then, we exposed primary lung CD4+ T cells
from T-bet/ OVA/OVA-treated mice to increasing doses of
GL and measured IL-4 production in the supernatant. As
shown in Fig. 5D, GL inhibited the IL-4 production in the
supernatants of T-bet-deficient lung CD4+ T cells, indicating
that GL inhibited IL-4 via a T-bet-independent mechanism.
In addition, we noticed that the decrease of IL-4 in the pres-
ence of T-bet after in vitro treatment with GL did not follow
the classical linear dose-dependent decrease indicating an
interfering effect of T-bet on GL-mediated IL-4 inhibition
(data not shown). In contrast, in the absence of T-bet, GL-
mediated IL-4 suppression followed a dose–response curve,
indicating that T-bet might interact with pSTAT-3 on the IL-4
promoter.
GL inhibited IL-6 signaling and decreased the IL-17
production in the lung
Treg cells have been described as the opposite developmen-
tal pathway of a newly described subset of pro-inflammatory
CD4+ T cells known as Th17 because of releasing IL-17. We
then started to analyze Th17 cells in the lung of GL-treated
mice. TGF-b1 together with IL-10 reinforces Treg cell develop-
ment (30, 31) or in synergy with IL-6 it induces Th17 cells
(32). In accordance to this concept, we found significantly
decreased levels of IL-6 (Fig. 6A) in the BALF of GL-treated
mice. Furthermore, CD4+ T cells isolated from lungs of
GL (50 lg)-treated mice released significantly less IL-6
(Fig. 6B) and IL-17A (Fig. 6D) but increased levels of TGF-b1
(Fig. 6C) as compared with those isolated from control
untreated mice.
GL mediated the induction of lung FoxP3 and
IL-10-producing CD4+ T cells in vivo
We thus reasoned that the decreased activation state of lung
CD4+ T cells and the decreased number of Th17 cells (33)
after GL (50 lg) treatment could be accompanied by an in-
creased number of Treg cells as we found that GL led to
increased FoxP3 expression in the lungs of naive mice
(Fig. 1B). TGF-b1 is known to induce FoxP3 and accordingly,
TGF-b1 induction was accompanied by an increased amount
of Foxp3 (Fig. 7A) and of CD4+FoxP3+ T cells in the lung of
GL-treated mice (Fig. 7C). Furthermore, lung CD4+ T cells
isolated from GL-treated mice released five times as much
IL-10 as those isolated from untreated mice (Fig. 7B). In vitro
treated spleen CD4+ T cells also exhibited an enhanced
Treg cell phenotype (Fig. 7D, left panels) but this difference
although statistically significant was not that impressive. To
further investigate whether CD4+ T cells would become
Tregs (Foxp3+) because they are exposed to GL-treated
DCs, we co-incubated untreated splenic CD4+ T cells with
CD4 cells pre-treated with 250 lg ml1 GL. This resulted
in a 2-fold increase of FoxP3 expression in CD4+ T cells
(Fig. 7D, lower right panels). Taken together, these data
show an induction of Treg cells dependent on DCs upon
GL treatment (17, 34).
Reduction of SOCS-3 and IL-2 signaling after GL treatment
STAT-5 has been recently shown to inhibit IL-12-mediated Th1
cell development via SOCS-3 and STAT-3, resulting in Th2 cell
development (35). We next analyzed SOCS-3 in the lung of
untreated and GL-treated mice. GL is known to decrease
STAT-3 binding to target promoter, thus reduced SOCS-3 tran-
scriptional activation would reflect the lack of STAT-3 binding
to the target promoter. As shown in Fig. 8A, in vivo treatment
with GL resulted in decreased SOCS-3. Consistently, CD2-
specific STAT-3-deficient mice show decreased SOCS-3 ex-
pression in the lung, a signaling molecule inducing Th2 and
IL-17-producing cells (Fig. 8B) (36). We next investigated
whether pSTAT-5 was also decreased after GL treatment. As
shown in Fig. 8C, p-STAT-5 was decreased in the lung of GL-
treated mice as compared with untreated mice. Decreased
pSTAT-5 might reflect decreased IL-2. We thus next ana-
lyzed IL-2 levels in the presence or absence of T-bet in
the supernatants of lung CD4+/CD4- T cells isolated from
OVA-sensitized and -challenged wild-type and T-bet-
deficient mice. As shown, GL-treated T-bet/ CD4+ T cells
showed a significant decrease of IL-2 levels in their superna-
tants (Fig. 8D). Since low levels of IL-2 are known to induce
Treg cells, we conclude that also in the absence of T-bet,
GL could be used as an inducer of Treg cells (17, 37).
Discussion
Allergic asthma is a disease induced by allergens like pol-
len or house dust mite exposition in predisposed subjects
(38). Asthmatic patients are commonly treated with gluco-
corticoids (39) and to date the only alternative treatment is
restricted to allergen-mediated immunotherapy (40). Based
on the side-effects of glucocorticoid treatment such as gen-
eralized immune suppression, diabetes and osteoporosis
(41–43), we have focused on the new fungal compound
GL, a fungal metabolite from the ascomycete G. rufa (13).
We could show that GL inhibited STAT-3 signaling and AHR
by molecular mechanisms involving down-regulation of
pSTAT-5 resulting in CD4+Foxp3+ Treg cells induction in
treated mice. In fact, GL inhibited pSTAT-5 resulting in
reduced IL-2 production and IL-2 signaling in lung CD4+
T cells independently from T-bet. Furthermore, we describe
here that GL induced CD11c+CD123+ cells, thus creating
an anergic environment in which Treg cells (CD4+FoxP3+)
can develop and then may inhibit effective immunores-
ponses against the allergen. We also found that this effect
is mediated via inhibition of STAT-3 binding to its respon-
sive elements on the DNA resulting in SOCS-3 inhibition,
which is down-regulated in the absence of STAT-3 in T cells.
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Thus, down-regulation of pSTAT-5 and SOCS-3 resulted in
induction of Treg cells and inhibition of Th17 cells, thus
ameliorating experimental asthma.
The secondary fungal metabolite GL inhibited IL-6 signal-
ing pathways by blocking the binding of STAT-3 on several
cytokine promoters, leading to dysregulated cytokine re-
lease by different cell types as demonstrated for palindromic
activation sites inducing IFN-c production (44) and missing
activation of signal molecules (15). In naive mice, it was
found that GL (50 lg) treatment enhanced IFN-c and FoxP3
levels in the airways without affecting basal airway hyperres-
ponsiveness (AHR) and peribronchial inflammation. Similarly,
intra-nasal application of GL (50 lg) after allergen sensitiza-
tion and before and during the OVA challenge phase re-
duced AHR and goblet cell metaplasia in the lung as
characteristic features of experimental asthma. The immuno-
logical findings accompanying this amelioration of experi-
mental asthma are the induction of lung DCs producing
more IL-10 and IL-12p70, the expansion of regulatory CD4+
T cells co-expressing FoxP3 and a decrease of the Th17
cells in the airways of GL-treated mice.
IL-6 is a pro-inflammatory cytokine produced by DCs, mast
cells and B cells known to induce Th2 cell differentiation while
inhibiting Treg cells (45, 46). Consistently, we previously dem-
onstrated that local treatment with aIL-6R antibodies before
and during allergen challenge decreased the presence of ac-
tivated STAT-3 in the lung of aIL-6R-treated mice (47) as com-
pared with untreated mice. This molecular effect was
accompanied by decreased Th2 via apoptosis and increased
Treg cells in the lung of treated mice (12).
Fig. 8. GL treatment decreased IL-2 signal transduction and SOCS-3 in the lung in a murine model of asthma. (A) STAT-3 dysfunction after intra-
nasal GL (50 lg) therapy in mice reduced SOCS-3, which is known to induce Th2 responses in allergic diseases (P = 0.0029; n = 5). (B) Genetic
depletion of STAT-3 in T cells decreased SOCS-3 expression in lung tissue in a murine model of asthma (P = 0.045; n = 3). STAT-3flox/flox mice
were obtained from S. Akira and K. Takeda (Osaka University) and were described previously (18). (C) pSTAT-5 levels also were down-regulated
after GL (50 lg) in vivo in an acute model of allergic asthma (P = 0.041; n = 5). One representative experiment out of three is shown. (D) IL-2 was
decreased in the supernatants of lung CD4+ T cells treated with increasing doses of GL in vitro especially in T-bet-deficient CD4+ T cells
(P = 0.047; n = 3). Data are represented as mean values 6 SEM. *P < 0.05; **P < 0.01.
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Because GL induced IL-12p70 and IFN-c and decreased
the IL-6 in the airways, it could be considered as a novel
therapeutic approach for experimental allergic asthma be-
cause it recapitulated the effects of aIL-6R antibodies treat-
ment in vivo. Moreover, we demonstrated that the targets of
GL besides CD4+ T cells are DCs, which after treatment with
this pSTAT-3 and pSTAT-5 inhibitor produced more IL-12p70
and IL-10. These latter are predominant features in directing
a protective local Th1 immune response and reducing Th2
and Th17 cytokine production (48, 49). While aIL-4 antibody
treatment is known to suppress lung inflammation and AHR
in experimental asthma (21), endogenous IL-17 is essential
during antigen sensitization to establish allergic asthma
(48). Moreover, IL-17 has been shown to be regulated in an
IL-4-dependent manner since mice deficient in IL-4Ra
showed a marked decrease in IL-17 concentration with de-
creased eosinophil recruitment (50). More importantly, IL-17
deficiency seems to prevent development of allergic immune
responses in the human lung mediated by IL-4 (51, 52). GL
(50 lg) treatment reduced the production of the Th2 cytokine
IL-4 but also IL-17A (see Fig. 6D).
We thus reasoned that increased levels of IL-17-producing
CD4+ T cells in allergic disease may be secondary to de-
creased Th1 responses resulting in worsening of allergic lung
pathology (53, 54). To address this point, we analyzed IL-17A
production after GL treatment in the absence of T-bet in lung
CD4+ T-cell culture. We found, as shown for IL-2 and IL-4 in
this paper, that IL-17A is also inhibited in a dose–response
manner in the absence of T-bet by GL (Supplementary Figure
SIII is available at International Immunology Online). Finally,
we demonstrated that the inhibition of the Th2 component and
the induction of the Th1 cells in the lung of GL-treated mice
did not follow a classical dose-dependent inhibition in the
presence of T-bet. When GL was used in T-bet-deficient
CD4+ T cells, a dose response effect on IL-2, IL-4 and IL-17
inhibition was observed, indicating that T-bet interferes with
pSTAT-3 on the promoter of IL-2, IL-4 and IL-17 genes. This
observation will need further investigations.
Both, Treg cells development and Th17 inhibition were
proven to be linked to the inhibition of STAT-3–DNA binding,
which resulted in expansion of tolerogenic DC and Treg cell
differentiation while inhibiting Th17 pathways (55).
The expression of SOCS-3, a well-known target gene
of STAT-3 (56), regulates onset and maintenance of Th2-
mediated allergic responses and was reduced by this fungal
compound and led to a decrease of Th2 T-cell development
(15). The decrease of SOCS-3 upon GL treatment is consis-
tent with the increase in CD4+Foxp3+ Treg cell number in
GL-treated mice. Consistently, it has been reported that
SOCS-3 inhibits Treg cell functions and it is down-regulated
in Treg cells (57). Consistent with our results, it has
been shown that SOCS-3-deficient CD4+ T cells
produced more TGF-b and IL-10 but less IL-4 than control
T cells (36).
Our data are consistent with a role of STAT-3 described by
Radojcic et al. (58) in graft versus host disease (GVHD) in
a murine model. In this study, it was demonstrated that
STAT-3 signaling in donor mature T cells provides a direct
link between alloreactive T-cell-mediated tissue damage and
favorable Treg reconstitution post-transplant. Moreover, in
this model, STAT-3 ablation in alloreactive T cells limits their
in vivo proliferation and expansion in the secondary lym-
phoid tissues via expansion of the Treg cells. A high T-cell
proliferative rate is known to correlate with acute GVHD,
and the control of alloreactive T-cell proliferation is the aim
of many therapies used for GVHD prophylaxis after allogenic
bone marrow transplantation. However, these data are
different from those reported by Pallandre et al. (59) and an
explanation for that could be that GL targets different cell
types as those achieved with small interfering RNA strate-
gies. In fact, we demonstrated in this paper that GL targeted
preferentially DCs and T cells.
Moreover, consistent with our results, in tumor setting, in-
activation of STAT-3 in hematopoietic cells results in the
repression of IL-23 production by tumor-associated macro-
phages and DCs and up-regulation of IL-12 production in
DCs. Surprisingly, but consistent with the immune system
associated with the tumor, in that model an anti-tumor effect
of STAT-3 inhibition was in part due to decreased activity of
FoxP3+ Treg cells (60, 61).
In an allergic asthma model we found that inhibition of STAT-3
results in down-regulation of the IL-23 and IL-2 pathways, as
confirmed by the down-regulation of STAT-5 that results in
up-regulation of Treg cells and down-regulation of Th17 cells.
In conclusion, the inhibition of the STAT-3/STAT-5/SOCS-3-
dependent feedback loop after therapy in mice is an
important step toward a local therapy for allergic diseases
including an inhibition of the Th2 development combined
with an up-regulation of the Treg cells/Th1 differentiation
while suppressing IL-17.
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